Lisata Therapeutics ( (LSTA) ) has provided an announcement.
On May 8, 2025, Lisata Therapeutics announced its financial results for the first quarter of 2025 and provided a business update. The company highlighted positive outcomes from its ASCEND trial, with encouraging results from Cohort A and upcoming presentations for Cohort B. Lisata’s financial strategy has extended its cash runway into the third quarter of 2026, allowing continued development of certepetide, which has shown promise in enhancing the effectiveness of standard cancer treatments. The company is also progressing with multiple clinical trials globally, aiming to improve treatment outcomes for various solid tumors.
Spark’s Take on LSTA Stock
According to Spark, TipRanks’ AI Analyst, LSTA is a Neutral.
Lisata Therapeutics is navigating through financial difficulties with persistent losses and negative cash flows. The stock’s technical indicators and valuation reflect a challenging financial position. However, recent advancements in clinical trials and regulatory achievements offer potential upside, albeit with high risk.
To see Spark’s full report on LSTA stock, click here.
More about Lisata Therapeutics
Lisata Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on developing innovative therapies for the treatment of advanced solid tumors and other serious diseases. The company is actively involved in clinical and preclinical studies, particularly in evaluating the efficacy of their proprietary peptide, certepetide, in combination with various anti-cancer agents.
Average Trading Volume: 13,367
Technical Sentiment Signal: Sell
Current Market Cap: $19.82M
For detailed information about LSTA stock, go to TipRanks’ Stock Analysis page.